
Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Scancell Holdings and keeping the price target at £3.30. Joseph Pantginis’s rating is based on Scancell’s encouraging Modi-1 results
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| SCNLF | ― | ― | ― | -22.96% |
| Name | Price | % Change | |
|---|---|---|---|
| ― | -22.96% |

Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Scancell Holdings and keeping the price target at £3.30. Joseph Pantginis’s rating is based on Scancell’s encouraging Modi-1 results

Scancell Holdings ( ($GB:SCLP) ) just unveiled an announcement. Scancell Holdings has confirmed that all resolutions at its latest general meeting were approved, paving the way for a share consolidation

The latest update is out from Scancell Holdings ( ($GB:SCLP) ). Scancell Holdings has issued seven new ordinary shares to chief executive Dr Phil L’Huillier to ensure its share capital

The latest announcement is out from Scancell Holdings ( ($GB:SCLP) ). Scancell reported progress across its immunotherapy pipeline, led by iSCIB1+, which has U.S. fast track status and regulatory clearance

Scancell Holdings ( ($GB:SCLP) ) has issued an announcement. Scancell Holdings has released a circular and called a general meeting for 20 October 2026 to seek shareholder approval for its

An update from Scancell Holdings ( ($GB:SCLP) ) is now available. Scancell Holdings has secured a loan facility of up to US$25 million from funds managed by BlackRock, adding a

The latest update is out from Scancell Holdings ( ($GB:SCLP) ). Scancell Holdings will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026, with management

An announcement from Scancell Holdings ( ($GB:SCLP) ) is now available. Scancell Holdings has secured UK Medicines and Healthcare Products Regulatory Agency authorization for a Phase 3 registrational trial of

An update from Scancell Holdings ( ($GB:SCLP) ) is now available. Scancell Holdings, a clinical-stage biotech group, specialises in innovative cancer immunotherapies, including its DNA ImmunoBody and Moditope platforms, alongside

The latest update is out from Scancell Holdings ( ($GB:SCLP) ). Scancell Holdings has confirmed that its retail offer, conducted via the Winterflood Retail Access Platform, was significantly oversubscribed and
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.